JP2024539265A - 製剤 - Google Patents

製剤 Download PDF

Info

Publication number
JP2024539265A
JP2024539265A JP2024524494A JP2024524494A JP2024539265A JP 2024539265 A JP2024539265 A JP 2024539265A JP 2024524494 A JP2024524494 A JP 2024524494A JP 2024524494 A JP2024524494 A JP 2024524494A JP 2024539265 A JP2024539265 A JP 2024539265A
Authority
JP
Japan
Prior art keywords
antibody
buffer
stable liquid
liquid formulation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539265A5 (https=
Inventor
クラウデ ピアボーム、
ミカエル ジョゼフ エデュアルド ボーネン、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of JP2024539265A publication Critical patent/JP2024539265A/ja
Publication of JP2024539265A5 publication Critical patent/JP2024539265A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2024524494A 2021-10-21 2022-10-20 製剤 Pending JP2024539265A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2115121.2 2021-10-21
GBGB2115121.2A GB202115121D0 (en) 2021-10-21 2021-10-21 Formulations
PCT/EP2022/079182 WO2023067049A1 (en) 2021-10-21 2022-10-20 Formulations

Publications (2)

Publication Number Publication Date
JP2024539265A true JP2024539265A (ja) 2024-10-28
JP2024539265A5 JP2024539265A5 (https=) 2025-10-21

Family

ID=78806158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524494A Pending JP2024539265A (ja) 2021-10-21 2022-10-20 製剤

Country Status (17)

Country Link
US (1) US20240415769A1 (https=)
EP (1) EP4419078A1 (https=)
JP (1) JP2024539265A (https=)
KR (1) KR20240099311A (https=)
CN (1) CN118119377A (https=)
AR (1) AR127421A1 (https=)
AU (1) AU2022372646A1 (https=)
CA (1) CA3235381A1 (https=)
CL (1) CL2024001229A1 (https=)
CO (1) CO2024006193A2 (https=)
GB (1) GB202115121D0 (https=)
GE (2) GEAP202416520A (https=)
IL (1) IL312207A (https=)
MX (1) MX2024004872A (https=)
PE (1) PE20241193A1 (https=)
TW (1) TW202323288A (https=)
WO (1) WO2023067049A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂

Also Published As

Publication number Publication date
AU2022372646A1 (en) 2024-06-06
GEAP202416520A (en) 2024-07-25
AR127421A1 (es) 2024-01-24
GB202115121D0 (en) 2021-12-08
GEP20257800B (en) 2025-09-25
CN118119377A (zh) 2024-05-31
TW202323288A (zh) 2023-06-16
CA3235381A1 (en) 2023-04-27
KR20240099311A (ko) 2024-06-28
US20240415769A1 (en) 2024-12-19
MX2024004872A (es) 2024-05-06
PE20241193A1 (es) 2024-06-03
IL312207A (en) 2024-06-01
EP4419078A1 (en) 2024-08-28
CL2024001229A1 (es) 2024-09-13
CO2024006193A2 (es) 2024-05-30
WO2023067049A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
JP6541581B2 (ja) 低濃度抗体製剤
AU2015260758B2 (en) Antibody formulation
US20060008415A1 (en) Stable liquid and lyophilized formulation of proteins
JP2018507202A (ja) モノクローナル抗体のための安定的な液体製剤
CN105051064A (zh) 抗TNF-α抗原结合蛋白
JP2022540781A (ja) 抗cd47/pd‐l1二重特異性抗体を含む製剤、その調製方法及び使用
KR20140066124A (ko) 점도가 감소된 제제
KR20140018966A (ko) 점도가 감소된 제제
US20240342083A1 (en) Anti-pd-1 antibody pharmaceutical composition and use thereof
KR20240109250A (ko) 항ox40 단일클론 항체를 포함하는 약학적 제제
WO2024240224A1 (zh) 包含抗ccr8抗体的制剂及其用途
JP2024539265A (ja) 製剤
JP2025526400A (ja) 抗tl1a抗体製剤
CN116459335A (zh) 抗cldn-18.2抗体药物组合物及其用途
JP2024539502A (ja) 製剤
HK40109650A (zh) 制剂
HK40109619A (zh) 制剂
RU2844800C2 (ru) Фармацевтическая композиция на основе антитела против PD-1 и ее применение
US20260008849A1 (en) Antibody formulations
BR122025018375A2 (pt) Fragmentos de cadeia única de anticorpo anti-c3
CN116763917A (zh) 一种稳定的抗人il15/pd-l1双功能融合蛋白制剂
HK40093161A (zh) 抗ctla-4抗体药物组合物及其用途
HK40118051A (zh) Csf-1r抗体制剂
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251010